Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III ...